Trial Profile
Paclitaxel in Combination With Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Mar 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Paclitaxel (Primary)
- Indications Haemangiosarcoma
- Focus Therapeutic Use
- 02 Jun 2017 Status changed from active, no longer recruiting to completed, according to results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 24 Jun 2014 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.